Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2789267 | 0.92 | DPP4 (0.34) | DPP4DPP8DPP9ALDH1A1TSHR | |
| SCHEMBL2790575 | 0.89 | DPP4 (0.37) | DPP4DPP8DPP9ALDH1A1TSHR | |
| SCHEMBL2789934 | 0.87 | DPP4 (0.34) | DPP4DPP8DPP9ALDH1A1TSHR | |
| SCHEMBL7890034 | 0.87 | DPP4 (0.35) | DPP4DPP8DPP9ALDH1A1TSHR | |
| SCHEMBL2789744 | 0.84 | DPP4 (0.34) | DPP4DPP8DPP9ALDH1A1TSHR | |
| SCHEMBL7899653 | 0.84 | DPP4 (0.34) | DPP4DPP8DPP9ALDH1A1TSHR | |
| SCHEMBL2793656 | 0.84 | DPP4 (0.34) | DPP4DPP8DPP9ALDH1A1TSHR | |
| SCHEMBL2789742 | 0.84 | DPP4 (0.34) | DPP4DPP8DPP9ALDH1A1TSHR | |
| SCHEMBL2818318 | 0.84 | PROKR1 (0.42) | DPP4ALDH1A1TSHRKMT2A | |
| SCHEMBL2816909 | 0.84 | PROKR1 (0.42) | DPP4ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010111634-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |